文献速递胸部肿瘤放疗放疗物理与技术

特发性间质性肺炎肺癌患者立体定向放疗的毒性与生存

Stereotactic body radiotherapy for lung cancer patients with idiopathic interstitial pneumonias.
PubMed 文献 · Radiother Oncol · 2017-09-14

该研究比较伴或不伴特发性间质性肺炎(IIP)的肺癌患者接受立体定向体部放疗(SBRT)后的毒性与生存,共纳入508例患者(42例伴IIP),中位随访32.3个月。伴IIP患者≥3级放射性肺炎发生率显著更高(12% vs. 3%,p=0.009),2年局部复发率两组均低(3.4% vs. 5.6%,p=0.38),但伴IIP患者2年总生存率显著更低(42.2% vs. 80.9%,p<0.001),肺癌死亡两组相当(p=0.74)。结论认为SBRT在伴IIP的肺癌患者中可实现良好局部控制且肺部毒性可接受。

要点

  • 伴IIP患者SBRT后≥3级放射性肺炎显著高于无IIP者(12% vs. 3%,p=0.009)。
  • 两组2年局部复发率均低且无显著差异(3.4% vs. 5.6%,p=0.38)。
  • 伴IIP患者2年总生存率显著更低(42.2% vs. 80.9%,p<0.001),但肺癌死亡相当(p=0.74)。

核心结论

  • SBRT在伴IIP的肺癌患者中实现良好局部控制且肺部毒性可接受,可作为早期肺癌伴IIP患者的合理选择。

研究设计与样本

  • 回顾性分析2005至2016年接受SBRT的肺癌患者,纳入总剂量40-60Gy/5次、根治性意图、cT1-4N0M0或术后孤立局部复发者,共508例,其中42例伴IIP。

主要发现

  • 伴IIP患者≥3级放射性肺炎发生率显著高于无IIP者(12% vs. 3%,p=0.009)。
  • 两组2年局部复发率均低(3.4% vs. 5.6%,p=0.38)。
  • 伴IIP患者2年总生存率显著更低(42.2% vs. 80.9%,p<0.001),但肺癌死亡两组相当(p=0.74)。
  • 中位随访32.3个月(范围6.0-120.9个月)。

临床怎么用

  • 对伴IIP的早期肺癌患者,SBRT可作为根治性治疗选择,但需警惕≥3级放射性肺炎风险升高。
  • 治疗决策时应权衡伴IIP患者总生存较差但肺癌死亡未增加的特点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare toxicity and survival after stereotactic body radiotherapy (SBRT) between lung cancer patients with or without idiopathic interstitial pneumonias (IIPs), and to investigate the potential value of SBRT for the patients. METHODS: Among lung cancer patients receiving SBRT between 2005 and 2016, we evaluated those treated with a total dose of 40-60Gy in five fractions with curative intent who either were staged as cT1-4N0M0 or experienced postoperative isolated local recurrence. We analyzed the incidence of radiation pneumonitis (RP) in all patients and local recurrence and overall survival (OS) in T1a-2a patients. RESULTS: A total of 508 patients were eligible, including 42 with IIPs. The median follow-up was 32.3 (6.0-120.9) months. Significantly more patients with IIPs had grade ≥3RP than did those without IIPs (12% vs. 3%, p=0.009). The 2-year local recurrence rate was low in both groups (3.4% vs. 5.6%, p=0.38). The 2-year OS rate was significantly lower in the patients with IIPs (42.2% vs. 80.9%, p<0.001), although death from lung cancer was comparable (p=0.74). CONCLUSION: SBRT achieved excellent local control with acceptable pulmonary toxicity in lung cancer patients with IIPs. SBRT can be a reasonable option for early lung cancer patients with IIPs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tsurugai Y, Takeda A, Sanuki N, et al. Stereotactic body radiotherapy for lung cancer patients with idiopathic interstitial pneumonias. Radiother Oncol. 2017. PMID: 28919004. doi:10.1016/j.radonc.2017.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。